Europe — EMA
Ozempic (Semaglutide)
Semaglutide, the active ingredient in Ozempic, is a glucagon-like peptide‑1 (GLP‑1) receptor agonist presented as a subcutaneous injection for weekly use.
Request sourcing
What is Semaglutide?
Semaglutide, the active ingredient in Ozempic, is a glucagon-like peptide‑1 (GLP‑1) receptor agonist presented as a subcutaneous injection for weekly use. It improves blood glucose control in adults with type 2 diabetes and may reduce cardiovascular risk. GNH USA supplies Ozempic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Ozempic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Semaglutide used for?
Ozempic is a GLP‑1 receptor agonist indicated for metabolic conditions that involve glucose regulation.
- Type 2 diabetes mellitus: improves glycaemic control and lowers HbA1c levels. - Cardiovascular risk reduction: decreases the incidence of major adverse cardiovascular events in adults with established cardiovascular disease. - Weight management adjunct: used as an adjunct to diet and exercise to achieve weight loss in adults with obesity or overweight with at least one weight‑related comorbidity.
What are the side effects of Semaglutide?
Adverse reactions to Ozempic vary in frequency and severity.
Common Side Effects: - Nausea: mild to moderate, often transient. - Vomiting: may accompany nausea. - Diarrhea: typically self‑limiting. - Constipation: occasional. - Abdominal pain: mild discomfort. - Decreased appetite: reduced food intake.
Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Acute kidney injury: sudden decline in renal function. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Thyroid C‑cell tumours: potential risk, observed in rodent studies. - Diabetic retinopathy complications: worsening of pre‑existing eye disease. - Gallbladder disease: cholelithiasis or cholecystitis.
What precautions apply to Semaglutide?
When prescribing Ozempic, clinicians should consider several safety aspects.
- Renal impairment: dose adjustment may be required. - Gastrointestinal history: monitor for persistent nausea or vomiting. - Thyroid disease: avoid in patients with a personal or family history of medullary thyroid carcinoma. - Pregnancy: contraindicated ; discuss alternative therapy. - Breastfeeding: not recommended ; weigh benefits and risk. Store at 2-8°C: keep refrigerated
What does Semaglutide interact with?
Ozempic may interact with other medications.
Major Interactions (Avoid): - "); -
Product details
Related products

Ozempic 1.34 mg/mL
Semaglutide · 1.34 mg/mL

Ozempic .68 mg/mL
Semaglutide · 0.68 mg/mL

Ozempic .68 mg/mL
Semaglutide · 0.68 mg/mL

WEGOVY 1 mg/.5mL
Semaglutide · 1 mg/0.5 mL